Literature DB >> 16871032

Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.

Prahbjot Kaur1, Michael Mulvaney, J Andrew Carlson.   

Abstract

Neoplastic progression is characterized in part by escape from immune surveillance and formation of growth-permissive stroma. Basal cell carcinoma (BCC) can be subclassified into low- and high-risk types for local recurrence. To determine whether these types of BCC correlate with alterations in local host immune response and stroma and whether these changes follow stepwise histologic progression from low- to high-risk subtypes, we assessed the clinicopathologic features in 175 consecutive primary (nonrecurrent) BCC excision specimens. BCCs exhibited a significantly higher frequency of mixed rather than homogeneous growth patterns (76% vs. 24%, P=0.0001). Nodular (84%) was the most common pattern identified followed by superficial (77%), infiltrative (27%), morpheic (5%) and micronodular patterns (4%). Only superficial (12% of all BCC) and nodular (12%) patterns were identified in BCC with a homogeneous histologic phenotype. Micronodular and infiltrative-morpheic patterns were not identified together in mixed patterned BCCs, and these high-risk types were contiguous with nodular BCC. Superficial predominant BCC (major growth pattern) was significantly associated with trunk and extremity location (76%) and skin without solar elastosis (82%), whereas BCC harboring a nodular growth pattern component was significantly associated with a head and neck location (63%) and the presence of adjacent solar elastosis (all P< or =0.03). Significant correlations were identified for BCC subtypes with inflammatory and stromal alterations: superficial BCC with old regression and moderate to dense peritumoral lymphocytic infiltrates; high-risk types correlated with active regression; infiltrative and morpheic BCC with fibrosing tumor stroma; and micronodular BCC with loss of both host inflammatory and stromal tumor responses. Evaluating the theoretical histologic stepwise model of BCC progression (superficial-to-nodular-to-micronodular, or superficial-to-nodular-to-infiltrative-to-morpheic BCC types) revealed significant linear correlations with host response and alterations of tumor stroma (r=0.54, P=0.0001). BCC exhibit distinct epithelial-stromal-inflammatory patterns that correlate with BCC subtype and tumor progression. This ostensible pathway of diminishing host response and gain of permissive tissue environment highlights neoplastic evolution from low to high risk for local recurrence of BCC and implicates a histologic continuum reflecting dynamic host-BCC interactions.

Entities:  

Mesh:

Year:  2006        PMID: 16871032     DOI: 10.1097/00000372-200608000-00002

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  13 in total

1.  Basal cell carcinoma: stressful life events and the tumor environment.

Authors:  Christopher P Fagundes; Ronald Glaser; Sheri L Johnson; Rebecca R Andridge; Eric V Yang; Michael P Di Gregorio; Min Chen; David R Lambert; Scott D Jewell; Mark A Bechtel; Dean W Hearne; Joel B Herron; Janice K Kiecolt-Glaser
Journal:  Arch Gen Psychiatry       Date:  2012-06

2.  Dermal changes in superficial basal cell carcinoma, melanoma in situ and actinic keratosis and their implications.

Authors:  Viktoryia Kazlouskaya; Saurabh Malhotra; Raquel Navarro; Karen Nguyen Wu; Marianna Shvartsbeyn; Chen Shengli; Jiang Gui; Dirk M Elston
Journal:  J Cutan Pathol       Date:  2013-10-03       Impact factor: 1.587

3.  CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas.

Authors:  Blanche Ka Ki Lo; Mei Yu; David Zloty; Bryce Cowan; Jerry Shapiro; Kevin John McElwee
Journal:  Am J Pathol       Date:  2010-03-12       Impact factor: 4.307

4.  Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing.

Authors:  Alberto Paniz-Mondolfi; Rajesh Singh; George Jour; Mandana Mahmoodi; A Hafeez Diwan; Bedia A Barkoh; Ronald Cason; Yve Huttenbach; Gustavo Benaim; John Galbincea; Rajyalakshmi Luthra
Journal:  Virchows Arch       Date:  2014-07-17       Impact factor: 4.064

5.  Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls.

Authors:  Sonja Boyd; Kalle Tolvanen; Susanna Virolainen; Tiina Kuivanen; Lauri Kyllönen; Ulpu Saarialho-Kere
Journal:  Virchows Arch       Date:  2007-11-22       Impact factor: 4.064

6.  Presence of ulceration, but not high risk zone location, correlates with unfavorable histopathological subtype in facial basal cell carcinoma.

Authors:  Ozben Yalcin; Engin Sezer; Fevziye Kabukcuoglu; Ayse Irem Kilic; Ahu Gulcin Sari; Asli Aksu Cerman; Ilknur Kivanc Altunay
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

7.  Tumor site immune markers associated with risk for subsequent basal cell carcinomas.

Authors:  Ronald Glaser; Rebecca Andridge; Eric V Yang; Arwa Y Shana'ah; Michael Di Gregorio; Min Chen; Sheri L Johnson; Lawrence A De Renne; David R Lambert; Scott D Jewell; Mark A Bechtel; Dean W Hearne; Joel Bain Herron; Janice K Kiecolt-Glaser
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

8.  Morphometric characteristics of basal cell carcinoma peritumoral stroma varies among basal cell carcinoma subtypes.

Authors:  Kyle Lesack; Christopher Naugler
Journal:  BMC Dermatol       Date:  2012-03-09

9.  Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma.

Authors:  Michal Sobjanek; Ewa Bien; Monika Zablotna; Malgorzata Sokolowska-Wojdylo; Monika Sikorska; Magdalena Lange; Roman Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837

10.  Conventional Versus Giant Basal Cell Carcinoma, a Review of 57 Cases: Histologic Differences Contributing to Excessive Growth.

Authors:  J Chase Purnell; Jerad M Gardner; J Ahmad Brown; Sara C Shalin
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.